| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to… |
Trial terminated |
| 2026-06-12 | NCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to… |
date change Primary completion moved earlier: 2027-07-15 -> 2026-05-15 |
| 2026-06-12 | NCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to… |
date change Completion moved earlier: 2029-07-15 -> 2026-05-15 |
| 2026-06-09 | NCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in… |
Enrollment increased: 448 -> 530 participants |
| 2026-06-03 | NCT07166094 Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's… |
Trial sites expanded: 74 -> 81 locations |
| 2026-06-03 | NCT07225270 Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to… |
Trial sites expanded: 10 -> 13 locations |
| 2026-06-03 | NCT07288177 Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell… |
Trial sites expanded: 15 -> 22 locations |
| 2026-06-03 | NCT07387068 Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With… |
Trial sites expanded: 7 -> 11 locations |
| 2026-05-28 | NCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in… |
Enrollment reduced: 530 -> 448 participants |
| 2026-05-27 | NCT05579366 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/… |
Primary endpoint(s) modified |
| 2026-05-27 | NCT05579366 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/… |
Enrollment increased: 764 -> 884 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-22 | NCT07604766 An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of… | Phase 3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… | Follicular Lymphoma (FL) | Recruiting |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's… | Endometrial Cancer | Recruiting |
| NCT07225270 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to… | Ovarian Cancer | Recruiting |
| NCT06508658 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting |
| NCT07226752 | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting |
| NCT04628494 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in… | Diffuse Large B-cell Lymphoma | Active, Not Recruiting |
| NCT06635824 | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of… | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Active, Not Recruiting |
| NCT07604766 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of… | Platinum-resistant Ovarian Cancer | Not Yet Recruiting |
| NCT07564141 | Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to… | Platinum-Sensitive Ovarian Cancer | Not Yet Recruiting |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in… | Platinum-resistant Ovarian Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05283720 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC)… | Non-Hodgkin Lymphoma | Recruiting |
| NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell… | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT07539311 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced… | Gastrointestinal Cancers | Recruiting |
| NCT05117242 | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With… | Non Small Cell Lung Cancer Metastatic | Active, Not Recruiting |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/… | High Grade Epithelial Ovarian Cancer | Recruiting |
| NCT03917381 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Solid Tumors | Active, Not Recruiting |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell… | DLBCL | Active, Not Recruiting |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | Malignant Solid Tumor | Active, Not Recruiting |
| NCT04542824 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or… | Diffuse Large B Cell Lymphoma | Active, Not Recruiting |
| NCT04623541 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic… | Relapsed/Refractory Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT04663347 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT07384715 | First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid… | R/R AML | Recruiting |
| NCT07387068 | Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With… | Advanced Solid Tumors | Recruiting |
| NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | Solid Tumors | Recruiting |